



Ocular Therapeutix™ Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer

January 11, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Jonathan H. Talamo, M.D. to the position of Chief Medical Officer. In this role, Dr. Talamo will help advance Ocular's development pipeline, including lead therapeutic candidate, DEXTENZA™.

"Jonathan brings a wealth of expertise to Ocular during an exciting time in our Company's growth, and we are excited to welcome him to the team," said Dr. Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman of Ocular. "Since the acceptance by the FDA of our NDA submission of DEXTENZA for the treatment of post-surgical ocular pain in the fourth quarter of 2015, we have been preparing for its potential commercialization, as well as advancing the DEXTENZA platform in allergic conjunctivitis and dry eye and OTX-TP for glaucoma. Jonathan is an internationally-known and well regarded ophthalmologist whose experience as a practicing ophthalmic surgeon, coupled with his scientific advisory roles for numerous prominent ophthalmology companies, will be valuable as we continue to advance through the clinical and regulatory process."

Dr. Talamo joins Ocular with more than 25 years of industry experience as an ophthalmologist, innovator and industry consultant. Dr. Talamo has advised many early to late stage ophthalmology companies such as Alcon/Novartis, Allergan, Bausch & Lomb, Shire, as well as Ocular, in the areas of product R&D, clinical trial design, regulatory issues, business development strategy, fund raising and marketing. He was an investigator for many of the early clinical trials that led to FDA approval of lasers for vision correction with PRK and LASIK as well as image guided lasers for refractive cataract surgery. Dr. Talamo currently serves as an Associate Professor of Ophthalmology at Harvard Medical School and as Director of the Massachusetts Eye and Ear Infirmary (MEEI) Waltham, a Harvard-affiliated teaching hospital. Dr. Talamo is also Chairman of the Program Committee and on the Executive Board of the New England Ophthalmological Society. He was a recipient of Honor and Senior Achievement awards from the American Academy of Ophthalmology for his clinical research and teaching expertise. Dr. Talamo received his M.D. degree from The Johns Hopkins University School of Medicine and completed an ophthalmology residency at the Wilmer Ophthalmological Institute of The Johns Hopkins Hospital. Dr. Talamo completed a clinical fellowship in cornea and external disease at Massachusetts Eye and Ear Infirmary.

"I believe Ocular has tremendous potential and am thrilled to be joining at a time when the pipeline consists of several mid and late-stage clinical programs," said Dr. Talamo. "I look forward to helping to advance its proprietary hydrogel technology for patients who can benefit from sustained-release therapies."

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been accepted by the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. For glaucoma and ocular hypertension, OTX-TP (sustained release travoprost) intracanalicular depot, has completed a Phase 2b clinical trial. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the advancement, development or potential launch and commercialization of the Company's product candidates, the potential for the Company's sustained release hydrogel depot technology, the Company's plans for or success with regulatory submissions, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company's scientific approach and general development progress, the availability or commercial potential of the Company's product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

Source: Ocular Therapeutix, Inc.

Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media:

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com